Epidermal growth factor receptor as a therapeutic target in veterinary oncology

Veterinary and Comparative Oncology

Volumn 9, Issue 2, 2011, Pages 81-94

  Bergkvist, G T ^a   Yool, D A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

EGFR tyrosine kinase; Glioma; Mammary carcinoma; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; BRAIN TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; GLIOMA; HUMAN; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; BRAIN NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; GLIOMA; HUMANS; MAMMARY NEOPLASMS, ANIMAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 79956044486     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00237.x     Document Type: Review

References (94)

1. Graus-Porta D, Beerli RR, Daly JM and Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO Journal 1997; 16: 1647-1655.
2. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Downward J, Mayes ELV, Whittle N, Waterfield MD and Seeburg PH. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425.
3. Lurje G and Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77: 400-410.
4. Baselga J and Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 2009; 9: 463-475.
5. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim J-H, Saito K, Sakamoto A, Inoue M, Shirouzu M and Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-787.
6. Sorkin A and Goh LK. Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research 2009; 315: 683-696.
7. Yarden Y and Sliwkowski MX. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2001; 2: 127-137.
8. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. The EMBO Journal 1998; 17: 3385-3397.
9. Henson ES and Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cellular Signalling 2006; 18: 2089-2097.
10. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M and Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-787.
11. Citri A, Skaria KB and Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Experimental Cell Research 2003; 284: 54-65.
12. Salomon DS, Brandt R, Ciardiello F and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology 1995; 19: 183-232.
13. Rogers SJ, Harrington KJ, Rhys-Evans P, P OC and Eccles SA. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Reviews 2005; 24: 47-69.
14. Lu X and Kang Y. Epidermal growth factor signalling and bone metastasis. British Journal of Cancer 2009; 102: 457-461.
15. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY and Grandis JR. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003; 22: 6183-6193.
16. Accornero P, Martignani E, Miretti S, Cucuzza LS and Baratta M. Epidermal growth factor and hepatocyte growth factor receptors collaborate to induce multiple biological responses in bovine mammary epithelial cells. Journal of Dairy Science 2009; 92: 3667-3675.
17. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
18. Grandis JR and Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research 1993; 53: 3579-3584.
19. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B and Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Development 1998; 12: 3663-3674.
20. Song JI and Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19: 2489-2495.
21. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-2008.
22. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Experimental Cell Research 2003; 284: 122-130.
23. Kalyankrishna S and Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. Journal of Clinical Oncology 2006; 24: 2666-2672.
24. Grandis JR, Melhem MF, Barnes EL and Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-1292.
25. Pan J, Kong L, Lin S, Chen G, Chen Q and Lu JJ. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. The Laryngoscope 2008; 118: 1970-1975.
26. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC and Elledge RM. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010; 116: 1234-1242.
27. Gan HK, Kaye AH and Luwor RB. The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience 2009; 16: 748-754.
28. Furuse J. Growth factors as therapeutic targets in HCC. Critical Reviews in Oncology/Hematology 2008; 67: 8-15.
29. John T, Liu G and Taso M-S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009; 28: S14-S23.
30. Nicholson RI, Gee JM and Harper ME. EGFR and cancer prognosis. European Journal of Cancer 2001; 37: S9-S15.
31. Dei Tos AP and Ellis I. Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods? European Journal of Cancer 2005; 41: 1383-1392.
32. Reuter CW, Morgan MA and Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. British Journal of Cancer 2007; 96: 408-416.
33. Roberts PJ and Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310.
34. Thariat J, Yildirim G, Mason KA, Garden AS, Milas L and Ang KK. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. International Journal of Clinical Oncology 2007; 12: 99-110.
35. Nissim A and Chernajovsky Y. Historical development of monoclonal antibody therapeutics. In: Therapeutic Antibodies, Y Chernajovsky and A Nissim, eds., Berlin, Heidelberg, Springer, 2008: 3-18.
36. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gason P, Amellal A and Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2005; 23: 5568-5577.
37. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2006; 354: 567-578.
38. Jimeno A and Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity. Critical Reviews in Oncology/Hematology 2005; 53: 179-192.
39. Bernier J and Schneider D. Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? European Journal of Cancer 2007; 43: 35-45.
40. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margond B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine 2009; 361: 947-957.
41. Pircher A, Ploner F, Popper H and Hilbe W. Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer 2010; 69: 265-271.
42. Li C, Iida M, Dunn EF, Ghia AJ and Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28: 3801-3813.
43. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27: 3944-3956.
44. Chaturvedi D, Gao X, Cohen MS, Taunton J and Patel TB. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene 2009; 28: 1187-1196.
45. Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, et al. PTEN status in advanced colorectal cancer treated with cetuximab. British Journal of Cancer 2009; 102: 162-164.
46. Sharma SV, Bell DW, Settleman J and Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007; 7: 169-181.
47. Normanno N, Bianco C, de Luca A, Strizzi L, Gallo M, Mancino M, et al. Expression and prognostic significance of the EGFR in solid tumours. In: EGFR Signalling Networks in Cancer Therapy, 1st edn., JD Haley and WJ Gullick, eds., New York, Humana Press, 2008: 221-234.
48. Raica M, Jung I, Cimpean AM, Suciu C and Mureşan AM. From conventional pathologic diagnosis to the molecular classification of breast carcinoma: Are we ready for change? Romanian Journal of Morphology and Embryology 2009; 50: 5-13.
49. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B and Di Renzo MF. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research 2005; 65: 907-912.
50. Gama A, Gartner F, Alves A and Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Research in Veterinary Science 2009; 87: 432-437.
51. Minke JM, Schuuring E, van den Berghe R, Stolwijk JA, Boonstra J, Cornelisse C, Hilkens J and Misdorp W. Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors. Cancer Research 1991; 51: 4028-4037.
52. Queiroga FL, Perez-Alenza D, Silvan G, Pena L and Illera JC. Positive correlation of steroid hormones and EGF in canine mammary cancer. The Journal of Steroid Biochemistry and Molecular Biology 2009; 115: 9-13.
53. Matsuyama S, Nakamura M, Yonezawa K, Shimada T, Ohashi F, Takamori Y and Kubo K. Expression patterns of the erbB subfamily mRNA in canine benign and malignant mammary tumors. The Journal of Veterinary Medical Science/the Japanese Society of Veterinary Science 2001; 63: 949-954.
54. Donnay I, Devleeschouwer N, Wouters-Ballman P, Leclercq G and Verstegen J. Relationship between receptors for epidermal growth factor and steroid hormones in normal, dysplastic and neoplastic canine mammary tissues. Research in Veterinary Science 1996; 60: 251-254.
55. Nerurkar VR, Seshadri R, Mulherkar R, Ishwad CS, Lalitha VS and Naik SN. Receptors for epidermal growth factor and estradiol in canine mammary tumors. International Journal of Cancer 1987; 40: 230-232.
56. Rutteman GR, Foekens JA, Portengen H, Vos JH, Blankenstein MA, Teske E, Cornelisse CJ and Misdorp W. Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Research and Treatment 1994; 30: 139-146.
57. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Experimental Cell Research 2003; 284: 78-88.
58. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Van De Rijn M and Perou CM. Immunohistochemical and clinical characterisation of the basal-like subtype of invasive breast cancer. Clinical Cancer Research 2004; 10: 5367-5374.
59. O'Brien CS, Howell SJ, Farnie G and Clarke RB. Resistance to endocrine therapy: Are breast cancer stem cells the culprits? Journal of Mammary Gland Biology and Neoplasia 2009; 14: 45-54.
60. Gama A, Alves A and Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Archive 2008; 453: 123-132.
61. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Reviews 2005; 24: 9-17.
62. Mrhalova M, Plzak J, Betka J and Kodet R. Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005; 52: 338-343.
63. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JMG, D'Silva NJ, Yang K, Kurnit DM, Bradford CR and Carey TE. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. International Journal of Radiation Oncology, Biology, Physics 2007; 69: S109-S111.
64. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR and Wilson GD. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. Journal of Clinical Oncology 2005; 23: 5560-5567.
65. Eriksen JG, Steiniche T, Askaa J, Alsner J and Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. International Journal of Radiation Oncology, Biology, Physics 2004; 58: 561-566.
66. Kapatkin AS, Maretta SM, Patnaik AK, Burk RL and Matus RE. Mandibular swelling in cats: prospective study of 24 cats. Journal of the American Animal Hospital Association 1991; 27: 575-580.
67. Stebbins KE, Morse CC and Goldschmidt MH. Feline oral neoplasia: a ten-year survey. Veterinary Pathology 1989; 26: 121-128.
68. Looper JS, Malarkey DE, Ruslander D, Proulx D and Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Veterinary and Comparative Oncology 2006; 4: 33-40.
69. Dhaliwal RS and Kufuor-Mensah E. Metastatic squamous cell carcinoma in a cat. Journal of Feline Medicine and Surgery 2007; 9: 61-66.
70. Hayes AM, Adams VJ, Scase TJ and Murphy S. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. Journal of Small Animal Practice 2007; 48: 394-399.
71. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Hsu TC, Schantz SP. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention 2000; 9: 1043-1049.
72. Bertone ER, Snyder LA and Moore AS. Environmental and lifestyle risk factors for oral squamous cell carcinoma in domestic cats. Journal of Veterinary Internal Medicine 2003; 17: 557-562.
73. Snyder LA, Bertone ER, Jakowski RM, Dooner MS, Jennings-Ritchie J and Moore AS. p53 Expression and environmental tobacco smoke exposure in feline oral squamous cell carcinoma. Veterinary Pathology 2004; 41: 209-214.
74. Wikstrand CJ and Bigner DD. Constitutive activation of truncated EGF receptors in glioblastoma. In: EGFR Signaling Networks in Cancer Therapy, JD Haley and WJ Gullick, eds., New York, Humana Press, 2008: 277-292.
75. Thomas R, Duke SE, Wang HJ, Breen TE, Higgins RJ, Linder KE, Ellis P, Langford CF, Dickinson PJ, Olby NJ and Breen M. 'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. Journal of Neuro-Oncology 2009; 94: 333-349.
76. Higgins RJ, Dickinson PJ, Lecouteur RA, Bollen AW, Wang H, Wang H, Corely LJ, Moore LM, Zang W and Fuller GN. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. Journal of Neuro-Oncology 2010; 98: 49-55.
77. Dickinson PJ, Roberts BN, Higgins RJ, Leutenegger CM, Bollen AW, Kass PH, Le Couteur RA. Expression of receptor tyrosine kinases VEGFR-1 (FLT-1), VEGFR-2 (KDR), EGFR-1, PDGFRalpha and c-Met in canine primary brain tumours. Veterinary and Comparative Oncology 2006; 4: 132-140.
78. Lipsitz D, Higgins RJ, Kortz GD, Dickinson PJ, Bollen AW, Naydan DK and Le Couteur RA. Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs. Veterinary Pathology 2003; 40: 659-669.
79. Stoica G, Kim HT, Hall DG and Coates JR. Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas. Veterinary Pathology 2004; 41: 10-19.
80. Abdulamir AS, Hafidh RR, Kadhim HS and Abubakar F. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. Journal of Experimental & Clinical Cancer Research 2009; 28: 27.
81. Black PC and Dinney CPN. Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastasis Reviews 2007; 26: 623-634.
82. Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP and Mellon JK. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer. Clinical Oncology (Royal College of Radiologists) (Great Britain) 2006; 18: 702-709.
83. Landolfi JA and Terio KA. Transitional cell carcinoma in fishing cats (Prionailurus viverrinus): pathology and expression of cyclooxygenase-1, -2, and p53. Veterinary Pathology 2006; 43: 674-681.
84. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. Journal of Clinical Oncology 2005; 23: 6657-6663.
85. Grabarevic Z, Coric M, Seiwerth S, Dzaja P, Artukovic B, Kurilj AG, et al. Comparative analysis of hepatocellular carcinoma in men and dogs. Collegium Antropologicum 2009; 33: 811-814.
86. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaria M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Experimental Biology and Medicine (Maywood, NJ) 2009; 234: 713-725.
87. Shiomitsu K, Johnson CL, Malarkey DE, Pruitt AF and Thrall DE. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Veterinary and Comparative Oncology 2009; 7: 106-114.
88. Gillett NA, Stegelmeier BL, Kelly G, Haley PJ and Hahn FF. Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. Veterinary Pathology 1992; 29: 46-52.
89. Burris HA III. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 2009; 28: S4-S13.
90. Hirsch FR, Varella-Garcia M and Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009; 28: S32-S37.
91. Hudachek SF, Kraft SL, Thamm DH, Bielefeldt-Ohmann H, DeMartini JC, Miller AD, et al. Lung tumor development and spontaneous regression in lambs coinfected with Jaagsiekte sheep retrovirus and ovine lentivirus. Veterinary Pathology 2010; 47: 148-162.
92. Hahn KA, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008; 22: 1301-1309.
93. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009; 15: 3856-3865.
94. National Cancer Institute (2010) Available at: [last accessed 15 February 2010].